Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

46.2%

6 terminated/withdrawn out of 13 trials

Success Rate

45.5%

-41.2% vs industry average

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment reporting

Analytics

Phase 2
7(58.3%)
Phase 2/3
2(16.7%)
Phase 4
1(8.3%)
Phase 3
1(8.3%)
Phase 1/2
1(8.3%)
12Total
Phase 2(7)
Phase 2/3(2)
Phase 4(1)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT00548717Phase 2Terminated

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT00014664Phase 2Unknown

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: lead

NCT00279422Phase 2/3Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Role: collaborator

NCT00279435Phase 2/3Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Role: collaborator

NCT00267306Phase 1/2Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Role: collaborator

NCT00267709Phase 2Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Role: collaborator

NCT00267722Phase 2Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Role: collaborator

NCT00502294Phase 3Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Role: collaborator

NCT00099970Phase 2Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Role: lead

NCT00109161Phase 2Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Role: lead

NCT00281294Phase 2Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Role: lead

NCT00355901Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Role: lead

NCT00325793Phase 4Unknown

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Role: collaborator

All 13 trials loaded